Ghassan Abou-Alfa, MD
While the hepatocellular carcinoma (HCC) field shifted in 2018 with the addition of newly available treatment options, more pivotal research is on the way, said Ghassan K. Abou-Alfa, MD.
, Abou-Alfa, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed the rapidly evolving treatment options in HCC and other developments in GI cancers.
OncLive: What have been the biggest advancements made in the field of HCC?
: It has been a great year with regard to many malignancies. Specifically, in the hepatobiliary domain, we have seen many positive changes. We are going to continue hearing a lot about the advances [being made] in HCC.
... to read the full story